Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06644313
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB N2 Non-small Cell Lung Cancer NSCLC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB N2 Non-small Cell Lung Cancer NSCLC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
According to the 2024 edition of the NCCN guidelines and the 2023 edition of the CSCO guidelines perioperative treatment is recommended for patients with stage IIIA and IIIB T3N2 non-small cell lung cancer NSCLC Targeted therapies for NSCLC such as EGFR inhibitors and ALK inhibitors have been explored in the neoadjuvant setting For patients with MET alterations some have undergone preoperative MET inhibitor treatment achieving pathological downstaging followed by surgery resulting in R0 resection Therefore this is a prospective cohort single-center phase II clinical study to evaluate the efficacy and safety of Vebreltinib as a neoadjuvant treatment for patients with MET-altered stage IIIA-IIIB N2 NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None